Kornimate/medical-research-clean huggingface dataset:
walking stick exercise in patients underwent total knee arthroplasty

Conditions: Arthroplasty; Replacement; Knee Osteoarthritis

Summary: the purpose of this study is to examine whether the effect of "hiking poles exercise" on lower extremity muscular strength, knee range of motion, and quality of life in elderly patients underwent total knee arthroplasty

this is a longitudinal-experimental study. the data collection and analysis are in a single-blind manner. the study will be undertaken in the department orthopaedics of en chu kong hospital (approximate 500-bed regional teaching hospital). all patients who meet the inclusion criteria are admitted for primary total knee arthroplasty and assigned to control group or intervention group randomly. the 44 patients in the control group received routine guidance of " rehabilitation and precautions for artificial knee replacement ". in addition to the routine guidance, the 44 patients in the intervention group received educations of " hiking poles exercise " on the day before surgery and before discharge, as well as a follow-up call at least once a week after discharge.

Eligibility criteria:
minimum age: 60 years maximum age: 85years gender-based: all accepts healthy volunteers:no criteria: inclusion criteria: * age between 60 and 85 years * informed consent * receipt of elective unilateral primary knee arthroplasty surgery. exclusion criteria: * non-degenerative arthritis, including rheumatoid arthritis, or traumatic arthritis * patients receiving rehabilitation simultaneously * patients with other musculoskeletal or neurological problems, including fractures, parkinsonism, cerebrovascular events, or patients with multiple comorbidities * cancer patients receive chemotherapy * patients with the peri-operative complication that has an adverse effect on outcomes,for example: intra-operative fractures, thromboembolism, peri-operative infections, or phlebitis

Keywords: total knee arthroplasty walking stick exercise
observational pharmaco-epidemiology research & analysis

Conditions: Chronic Disease; HIV/AIDS; Liver Diseases; Inflammatory Bowel Diseases; Cardiovascular Diseases; Rheumatic Diseases; Neurodegenerative Diseases

Summary: greater advances are needed in two separate but related areas in healthcare: 1) the clinical decision support systems that complement the ehr use in support of routine patient care, population management and disease management; and 2) the use of the point-of-care observational data from the provider-patient encounter that support realworld medical research and healthcare quality measure assessment. real-world evaluations of treatments of chronic diseases in the context of comorbid conditions and special populations (minorities, women, mentally ill, and those with addiction) are limited. the purpose of the opera database is to help address this unmet need in clinical research.

objectives of opera 1. to research numerous chronic diseases (hiv, hcv, hbv currently and ibd and ra in the near future, with others as identified for further consideration) utilizing the opera® longitudinal database that consists of de-identified ehr data from numerous clinical practices in a variety of settings (e.g. solo practitioners, small groups, and hospitals). research will be ongoing and yield numerous individual analyses and reports that are authored by epidemiologists, practicing physicians, pharmaco-economists, and other researchers and will target scientific conferences and peer-reviewed medical journals for dissemination. 2. to use epidemiological, statistical, and data analysis methods and related research findings to deliver a sophisticated healthcare analytics reporting solution (chorus™) to clinicians.† 3. to enhance patient population management as well as disease management capabilities of the practicing physician. 4. to provide anonymous, nation-wide benchmarking of quality measures and key performance indicators (kpi) for medical clinics. 5. to enhance patient engagement with their physicians to deliver better health outcomes. 6. to evaluate whether engagement in care by patients with their physicians results in better outcomes for patients with chronic illness.

Eligibility criteria:
inclusion criteria: * patients who are treated in the practices who enroll and participate in the study * patients whose treatment is documented in the practice's electronic health record system exclusion criteria: * patients who opt out of opera
a pre-op window study evaluating anti-proliferative effects of atorvastatin on the endometrium

Conditions: Endometrial Cancer

Summary: this is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer.

this is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer. after recruitment is completed, 24 paired endometrial biopsies and hysterectomy specimens from endometrial cancer patients treated at university of north carolina at chapel hill will be retrospectively obtained from the department of pathology to serve as controls. these cases will be matched for stage and grade to the endometrial cancers of those women enrolled on this phase 0 clinical trial and will undergo the same immunohistochemical analysis. two previous phase 0 window studies of metformin in endometrial cancer have found no difference in ki-67 expression between preoperative endometrial biopsy and hysterectomy specimen in control patients, although a difference was seen in metformin treated patients. however, the investigators plan to include a control group to ensure that changes found between pre- and post-atorvastatin treated patients are due to the effects of this drug versus differences in the type of specimen examined (i.e. endometrial biopsy specimen obtained in clinic versus hysterectomy specimen obtained at the time of surgery). in addition, enrolled patients will undergo repeat endometrial biopsy post- atorvastatin treatment at the time of their surgical staging. thus, study investigators plan to compare pre-treatment endometrial biopsies to both post-treatment endometrial biopsies and hysterectomy specimens as well as have a historical control group.

Eligibility criteria:
inclusion criteria: * be between the ages of 18-75 years old * have a confirmed diagnosis of type i endometrial cancer (endometrioid) based on pre-operative endometrial biopsy or dilation and curettage (d\&c) * have a bmi \>30 * have no contraindication to short-term atorvastatin therapy * have a serum creatinine ≤ 1.0 mg/dl * have normal serum transaminase values (ast and alt) * need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging exclusion criteria: * are currently taking a statin or have taken a statin in the past 6 months or have a history of an allergic reaction or intolerance at any time to a statin * have a history of liver or renal dysfunction * have a history of alcoholism * are pregnant * are currently taking any hormonal therapy or have been on hormonal therapy in the past 4 weeks * are taking a drug that may significantly interact or influence the metabolism of atorvastatin * concomitant cyclosporine, gemfibrozil, telaprevir, or tipranavir/ritonavir use * history of stroke or transient ischemic attack in the preceding 6 months

Keywords: atorvastatin endometrium endometrial cancer
postoperative biceps strength and electromyographic activity after proximal biceps tenotomy versus tenodesis in patients with arthroscopic rotator cuff tear repair

Conditions: Biceps Tendon Lesion

Summary: the most important functions of the biceps brachii muscle are flexion and supination of the elbow. patients with a partial or complete rotator cuff tear often suffer a lesion of the long head of the biceps tendon (lhbt). the two most common surgical treatments options are tenotomy or tenodesis. this study is to assess the supination strength index (ssi) (the operated side in relation to the healthy side) after proximal biceps tenotomy versus tenodesis.

the most important functions of the biceps brachii muscle are flexion and supination of the elbow. patients with a partial or complete rotator cuff tear often suffer a lesion of the long head of the biceps tendon (lhbt). the two most common surgical treatments options are tenotomy or tenodesis. this study is to assess the supination strength index ssi (the operated side in relation to the healthy side) after proximal biceps tenotomy versus tenodesis.

Eligibility criteria:
inclusion criteria: * patient after an arthroscopic rotator cuff repair who underwent a biceps tenotomy or tenodesis * 1-4 years postoperative * written informed consent exclusion criteria: * inability to provide informed consent * previous biceps injury and or operation * contralateral biceps injury * neurological disorders potentially affecting upper extremity muscle strength.

Keywords: partial rotator cuff tear complete rotator cuff tear proximal biceps tenotomy proximal biceps tenodesis arthroscopic rotator cuff tear repair biceps strength in supination and flexion supination strength index ssi lesion of the long head of the biceps tendon (lhbt)
bilevel positive airway pressure (bipap) for the treatment of moderate to severe acute asthma exacerbations

Conditions: Asthma; Status Asthmaticus

Summary: bilevel positive airway pressure (bipap) is increasingly being reported as an effective and safe method of respiratory support for children with severe asthma exacerbations unresponsive to standard therapies and with impending respiratory failure. much of the evidence base supporting its use comes from retrospective observational studies, and there is currently a lack of data from randomized controlled trials to inform this practice. the investigators hypothesize that the use of bipap in children with moderate to severe asthma exacerbations could reduce the length of hospital stay, need for invasive ventilation, and use of intravenous bronchodilators. the investigators aim to test this hypothesis by randomizing children attending the emergency department with a moderate to severe clinical severity score refractory to inhaled bronchodilators to receive either bipap in addition to standard asthma care, or standard care alone.

children aged 2 - 18 years presenting to the emergency department (ed) with a moderate or severe asthma exacerbation (pediatric respiratory assessment measure (pram) of \> 3) who fail to improve clinically with standard ed management with inhaled salbutamol and ipratropium will be randomized to receive either standard asthma management according to our local severe asthma guideline or management with bipap in addition to standard care. both groups will receive a comparable dose of systemic steroid and hourly salbutamol inhalers with subsequent weaning according to pram score. patients randomized to receive bipap will be admitted to the pediatric intensive care unit (picu) and those randomized to the control group will be admitted to the medical ward. both groups will be monitored with 3-hourly pram scoring through the duration of their admission.

Eligibility criteria:
inclusion criteria: * 2-18 years old * admitted to bc children's hospital with a clinical diagnosis of an acute asthma exacerbation * pram score of \>3 following initial treatment with three rounds of inhaled salbutamol and ipratropium bromide, and one dose of systemic steroid * parents willing and able to sign consent * children over the age of 6 willing to provide assent exclusion criteria: * clinical suspicion of co-existing bacterial pneumonia: focal crackles or bronchial breathing, and/or major chest x-ray findings * impending respiratory failure at presentation requiring direct picu admission * receiving maintenance dose of oral steroid at time of hospital admission * any contraindication to bipap use including altered mental status, recent bowel surgery, intractable vomiting, or inability to protect airway * current tracheostomy, home ventilation (ippv or nippv) or home oxygen requirement * history of congenital heart disease or chronic respiratory disease (including bronchopulmonary dysplasia, cystic fibrosis, pulmonary hypertension) * craniofacial abnormality precluding the use of a tight fitting facial mask

Keywords: bipap
study of pimecrolimus treatment for atopic dermatitis of african american children

Conditions: Atopic Dermatitis

Summary: primecrolimus cream 1% is effective in the treatment of atopic dermatitis in african american children.


Eligibility criteria:
inclusion criteria: * african american children aged 2 to 17 years * mild to moderate atopic dermatitis exclusion criteria: * m-easi less than 3 at baseline * allergy to elidel or components * use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study. * previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment. * active skin infections. * immunocompromised patients. * previous history of skin cancer or lymphoma * any hypopigmentation in study areas * pregnant or breastfeeding * participation in another investigational trial

Keywords: african american children
evaluation of pre-exposure prophylaxis against hiv in alpine region

Conditions: Pre-Exposure Prophylaxis; HIV Seronegativity; Drug Combination

Summary: despite the implementation of a national strategy to prevent the transmission of the human immunodeficiency virus (hiv) combining prevention campaigns, condom use, early detection of hiv infections and recommendations for treatment as soon as possible, the number of new hiv-infected patients per year in france does not decrease. new hiv prevention strategies are therefore clearly needed. since 2009, several studies have shown that tenofovir disoproxil fumarate and emtricitabine (tdf/ftc), an antiretroviral therapy combining two nucleoside reverse transcriptase inhibitors used for the treatment of patients seropositive for hiv, has preventive activity on hiv transmission. these results enabled the tdf/ftc to obtain in france an extension of the marketing authorization in march 2017 for preexposure prophylaxis (prep) of hiv transmission among patients at high risk of contamination. since the approval, many studies around the world investigate the use of prep in routine practice, highlighting its effectiveness in real life. these studies describe the population of patients who benefit from prep in order to adapt their multidisciplinary care but also track the transmission of other sexually transmitted infections to prevent their emergence, given the observed decline in condom use. however, these studies are limited to big cities while prep is accessible in all territories. the rhône-alpes region is one of the three french regions that has been the most involved in the implementation of prep, one year after the ftc/tdf approval in france. given the geographical position of the investigators, both in province and close to switzerland, where the ftc/tdf is not authorized for prep, and the non-university nature of five of the six involved hospitals, the investigators would like to determine the profile of patients consulting in this region to benefit from prep. this analysis will also determine if the population at risk of the "alpine arc" region is similar to that observed in the other cohorts in order to adapt patient care.


Eligibility criteria:
inclusion criteria: * patient having initiated or wishing to initiate prep according to the recommendations of the french high authority of health in the centers involved in the collection of data * patient informed of the study and having indicated his non opposition for the collection of his health data exclusion criteria: * wardship patient * patient under curatorship * patient unable to give his non-opposition to the use of his health data

Keywords: tenofovir disoproxil fumarate and emtricitabine combination
non invasive brain evaluation and treatment for neuropathic pain

Conditions: Neuropathic Pain

Summary: this trial is designed to preliminary evaluate the efficacy and safety of nibs system for evaluation and treatment of neuropathic pain. the nibs system evaluates brain neuronal network activity and customizes a personalized treatment utilizing low current non invasive brain stimulation technology for neuropathic pain with central component. this is single meeting trial which includes brain activity evaluation and a single treatment and sham treatment. the goal of the study is to evaluate the central brain component of neuropathic pain subjects, and the effect of conventional tdcs treatment.

neuropathic pain is a pain which persists after nerve injury has healed and results from significant functional and structural changes in the nervous system similar to memory processes. as a result, neuropathic pain has been proposed to be "a persistence of the memory of pain and/or the inability to extinguish the memory of pain evoked by an initial inciting injury". a firm conclusion in the neurobiology of learning and memory is that different types of memory have distinct mechanisms (e.g., declarative memory vs procedural memory). a similar distinction can be made in pain: various chronic pain states have distinct central mechanisms . accumulating evidence suggests that chronic pain is a type of nociceptive memory mediated by structural and functional plasticity in by multiple pathways at cortical, subcortical, spinal, and peripheral levels.elucidating the basal neuronal signature of the person suffering from chronic pain enables to optimizing a treatment which in all studies was constant for all patients regardless of their basal activity in this study participants will undergo diagnosis of the personalized central manifestation characteristics of the neuropathic pain and evaluate the efficacy of a standard, most commonly used tdcs treatment, based on the diagnosis. for this purpose a single meeting will take place during which participants will undergo evaluation, sham treatment and standard tdcs treatment.

Eligibility criteria:
inclusion criteria: * neuropathic pain diagnosis by pain physician up to 3 months before trial onset. * current nprs\>4 exclusion criteria: * neurological illness causing structural brain damage (e.g. stroke, tia) * psychiatric disease * history of loss of consciousness * epilepsy or epilepsy in a first degree relative * medical implants * pregnancy
implementation and evaluation of a family-based intervention program for children of mentally ill parents

Conditions: Schizophrenia and Disorders With Psychotic Features; Mood Disorders; Neurotic Disorders; Personality Disorders; Substance-Related Disorders

Summary: in order to identify psychological stress in children and adolescents of mentally ill parents as early as possible, a special intervention program (chimps = children of mentally ill parents) was developed. the study at hand will implement this intervention program at five sites in germany and will further evaluate its effectiveness. the chimps intervention is assumed to reduce children's psychopathology and enhance their health related quality of life.

the main purpose of this study is to implement the manualized family intervention chimps (children of mentally ill parents) for children and adolescents of psychiatrically ill parents aged between 3 and 19 years at the seven participating centres in regular care. the intervention aims at reducing children's psychopathology and enhancing their quality of life in a sustainable way and, moreover, aims at introducing especially remarkable children and adolescents to an early intervention. the study represents a prospective, randomized and controlled multicenter study (rct), contrasting one intervention group and one control group (tau = treatment as usual) by measurements at baseline and after six, 12 and 18 months. within the data collection, the perspective of the psychiatrically ill parent, the partner, each child and the therapist will be considered. children between 3 and 9 years of age will be evaluated only by the parents and the therapist, from 10 years on, an additional self-report form will be filled out by the child. the measurement will be ruled out indirectly (for the pre-post-measurement) as well as directly (at the end of treatment). for each endpoint, one comprehensive mixed model will be fitted to the data containing the baseline value and further relevant patient characteristics as covariates, the random group as factor and cluster (center, therapy group, family) as random effect. missing values will be treated by direct imputation to allow an intention-to-treat analysis.

Eligibility criteria:
inclusion criteria: * family with at least one psychiatrically ill parent and at least one child between the age of 3 and 19 years * consent to participate in the study * sufficient knowledge of the german language of parents and children exclusion criteria: * severe psychiatric disorders and impairments with acute symptoms such as suicidal tendencies, massive self-injurious behaviour, acute psychotic symptoms etc., making a stationary treatment inevitable and making a ambulatory intervention appear contraindicated (these patients are placed in stationary treatment) * children with severe symptoms in the control group will be placed at a participating psychotherapist. nevertheless, they stay in the control group (as tau).

Keywords: children of mentally ill parents family intervention randomized controlled trial
covid-19 genomic sequencing for nosocomial outbreak investigations

Conditions: COVID-19; Molecular Sequence Variation; Nosocomial Infection

Summary: this is a tertiary care hospital-based prospective molecular epidemiology study in montreal, canada. when nosocomial transmission was suspected by local infection control teams' investigations, sars-cov-2 viral genomic sequencing was performed locally for all putative outbreak cases and contemporary controls. molecular and conventional epidemiology data were confronted in real time to improve understanding of covid-19 transmission and reinforce or adapt prevention measures.

this study will include infected healthcare workers (hcw) and patients for whom a nosocomial infection in chum is suspected. the chum laboratory is responsible for covid-19 diagnostic testing in all eligible hcw and patients. after initial diagnosis on standard pcr testing, samples are maintained at -80. viral rna is extracted and next-generation sequencing of the viral genome is performed using nanopore long read sequencing platform. preliminary data suggest that sars-cov-2 has a "molecular clock" of 2 single nucleotide polymorphism (snp) per month. the analysis and between-isolate comparaison of those snp among epidemiologically related cases will allow to support or refute the hypothesis of person to person nosocomial transmission. all infected patients will be matched 1:1 with contemporary community cases to provide a viral genome back catalog and better contextualize molecular epidemiology analyses. molecular clusters will be reported to infection prevention and control teams and resulting interventions will be monitored.

Eligibility criteria:
inclusion criteria: * hospitalized in the institution during the study period * healthcare workers in the institution during the study period exclusion criteria: * none
drug use investigation for xyzal®

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Summary: this post-marketing surveillance study (pms) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.


Eligibility criteria:
inclusion criteria: * must be the first time for taking levocetirizine tablet exclusion criteria: * as this is pms study, there are no exclusion criteria.